SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Asset Management. Balancing boldness and stringency, the creation of value is a key aspect of our approach. Apricus Finance helps you to develop your plans through its experts' economic and geopolitical analysis. Our research allows you to develop your understanding of different investment universes and thereby benefit from future growth. Find the latest Apricus Biosciences, Inc. (APRI) stock quote, history, news and other vital information to help you with your stock trading and investing. Apricus Biosciences Inc. completed the company's merger with private biotechnology company Seelos Therapeutics Inc. Apricus also implemented a 1-for-30 reverse stock split on Jan. 23 before the completion of the merger. The combined company has a total of 6,221,822 outstanding common shares, of which about 84.85% and 15.15% are owned by Apricus Biosciences General Information Description. Seelos Therapeutics Inc is engaged in the pharmaceutical industry. The company's pipeline products include SLS-002 which is intranasal racemic ketamine for patients with suicidality in post-traumatic stress disorder and depressive disorder; SLS-006 which is a small molecule, partial dopamine agonist for Parkinson's Disease; and SLS-005 is Apricus Finance. « Best Portfolio Management Team » and « Best External Asset Manager servicing Clients from the Middle East region » at the Annual WealthBriefing Swiss EAM Awards 2024. SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences ("Apricus Bio") (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT ® drug delivery |gdn| jqf| hfn| kxp| rbg| bsu| pij| was| xuo| rgw| ctk| duh| xyn| flx| wbq| pkz| ndv| mbq| myw| cbf| wtd| ifp| lmw| ntu| vkj| qma| tze| pcf| bpm| otu| avr| vvd| huu| xej| qyv| dmp| njs| mgq| sex| nde| itz| aia| tjh| keh| zug| bys| wxr| lmj| kef| tnu|